BENLYSTA (belimumab) is indicated for the treatment of:
patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy, and adult patients with active lupus nephritis who are receiving standard therapy.
Limitations Of Use
The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics. Use of BENLYSTA is not recommended in these situations.
400 mg 1 vial x 20mL
This is the last line in the description
